Clinical Trial Detail

NCT ID NCT02029443
Title ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

prolymphocytic leukemia

CLL/SLL

diffuse large B-cell lymphoma

Therapies

Acalabrutinib

Age Groups: adult

No variant requirements are available.